Price
$39.62-18.58%Social Signal Score
Analyst Ratings
39 analysts52-week range
- Last close
- $39.62
- Off 52w high
- -38.1%
- 200-day average
- $42.95
- vs 200-day
- -7.8%
Revenue
$79.19B+167.80%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Maziar Mike Doustdar
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 68,794
- Beta
- 0.35
- Country
- DK
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 3.66
Financials
Revenue
$79.19B+167.8%Net Income
$16.74B+92.4%EBITDA
$36.94B+217.4%Free Cash Flow
$28.10B+235.0%EPS (diluted)
$3.79+119.1%Shares Outstanding (diluted)
4.42B-12.3%Operating Expenses
$36.16BCash & Debt
$49.18BReturn of Capital
$20.54BDividend per Share
$0.58Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $309.06B | $102.43B | $23.06 |
| 2024 | $290.40B | $100.99B | $22.67 |
| 2023 | $232.26B | $83.68B | $18.67 |
| 2022 | $176.95B | $55.52B | $12.26 |
| 2021 | $140.80B | $47.76B | $10.40 |
| 2020 | $126.95B | $42.14B | $9.03 |
| 2019 | $122.02B | $38.95B | $8.21 |
| 2018 | $111.83B | $38.63B | $7.98 |
| 2017 | $111.70B | $38.13B | $7.71 |
| 2016 | $111.78B | $37.92B | $7.50 |
| 2015 | $107.93B | $34.86B | $6.78 |
| 2014 | $88.81B | $26.48B | $5.05 |
| 2013 | $83.57B | $25.18B | $4.70 |
| 2012 | $78.03B | $21.43B | $3.91 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from NVO's reported EPS growth of 14.6% a year over 13 years.
- EPS in 5 years
- $45.52
- Implied price
- $637.30
- Return from $38.77
- 75.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $316.85 — today's price is already 87.8% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 10 | 12 | 14 | 16 | 18 |
|---|---|---|---|---|---|
| 4.6% | 49.4% | 54.9% | 59.8% | 64.1% | 68.0% |
| 9.6% | 56.5% | 62.3% | 67.4% | 72.0% | 76.0% |
| 14.6% | 63.7% | 69.7% | 75.1% | 79.8% | 84.1% |
| 19.6% | 70.8% | 77.1% | 82.7% | 87.6% | 92.1% |
| 24.6% | 77.9% | 84.6% | 90.3% | 95.5% | 100.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+33.33%Social Signal Score
Mentions (100)
- Newsfool.com·2d ago·Neutral
Forget the Headlines: Novo Nordisk's (NVO) 4.6% Dividend Yield Is the Real Story for Patient Investors Eli Lilly's not the only GLP-1 game in town -- Novo Nordisk has an oral pill formulation. The company's shares are attractive, and the company is poised to grow.
View source ↗ - Newsseekingalpha.com·3d ago·Positive
Novo Nordisk: A Return To Growth May Be Just Around The Corner I maintain a Buy on Novo Nordisk A/S: a 10–11 forward P/E looks inexpensive given potential returning to growth. Two quarterly beats and raised guidance support modest NVO 2026 growth; stronger-than-expected 2027 guidance could help NVO regain momentum. I see CagriSema approval and a successful launch as critical to NVO closing the efficacy gap with Lilly and establishing an amylin first-mover advantage.
View source ↗ - Newsseekingalpha.com·4d ago·Neutral
Novo Nordisk: The Worst May Be Behind Novo Nordisk A/S remains a long-term Buy: its wide moat and falling capital expenditure support higher free cash flow. NVO raised 2026 free cash flow guidance to DKK 60–70 billion while guiding for adjusted sales and operating profit between a 2% decline and 2% growth. NVO's Wegovy pill and pipeline diversification support growth, although competition, pricing pressure, and semaglutide's 2032 patent expiration threaten sales.
View source ↗ - Newszacks.com·6d ago·Negative
NVO's Hemophilia A Treatment Gets EC Nod, Data Presented on CagriSema Novo secures EC approval for Frehemgo while CagriSema delivers up to 21% weight loss, adding momentum to its turnaround efforts amid intensifying obesity drug competition.
View source ↗ - Newswsj.com·6d ago·Negative
Novo Nordisk Shares Rise on Positive Weight-Loss Data, Hemophilia Drug Approval The Danish drugmaker released encouraging results from studies and European regulators approved a hemophilia treatment, pushing the stock higher premarket.
View source ↗ - Newsreuters.com·8d ago·Neutral
Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
View source ↗ - Newszacks.com·12d ago·Neutral
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
View source ↗ - Newsseekingalpha.com·13d ago·Positive
Novo Nordisk: Q3 Earnings Bust The Cannibalization Myth Novo Nordisk is rated BUY with a 6-12 month target price of $57.24, implying ~34% upside from $42.62. Q3 results disprove oral cannibalization fears; a 53% pill surge drove net patient additions, proving robust commercial market expansion. Moderating capital expenditures, expanding free cash flow, and Catalent integration provide a strong margin of safety against Eli Lilly's debt-funded infrastructure buildout.
View source ↗ - Newsfool.com·14d ago·Neutral
Novo Nordisk's Wegovy Pill Has Topped 5 Million Prescriptions. Is the Stock a Buy Now? Novo Nordisk was first to market with a GLP-1 weight-loss shot and pill. Novo Nordisk lost its early lead with the GLP-1 shot to Eli Lilly, but the Wegovy pill seems to be doing well despite Eli Lilly introducing its own pill.
View source ↗ - Newsmarketbeat.com·14d ago·Neutral
What Novo Nordisk A/S (NVO) Said on Its Q3 Earnings Call Novo Nordisk A/S NYSE: NVO raised its 2026 sales and profit outlook after third-quarter adjusted sales rose 4% to DKK 79.2 billion, supported by demand for its obesity treatments and expanding use of the Wegovy pill.
View source ↗ - Newsfool.com·15d ago·Neutral
Novo Nordisk Just Delivered Great News for Investors. Is a Comeback Finally Underway? Novo's third-quarter update was strong, largely due to its oral weight-loss pill. The company has several catalysts ahead that could help power strong results over the medium term.
View source ↗ - Newsseekingalpha.com·16d ago·Positive
Novo Nordisk Owns The Oral Weight Loss Market At 7.8x Operating Income Novo Nordisk A/S is upgraded to Strong Buy, driven by robust Q3 results and accelerating Wegovy pill adoption. Novo Nordisk trades at just 7.8x trailing operating income, well below pharma peers, supporting a value-driven investment thesis. Projected annualized returns exceed 18% through 2030, underpinned by expanding oral GLP-1 market share and pipeline momentum.
View source ↗ - Newszacks.com·17d ago·Neutral
NVO Q3 Earnings Call Highlights GLP-1 Growth and Raised Outlook Novo raises its 2026 outlook as Wegovy pill adoption accelerates, while Medicare-driven demand, pricing pressures and 2027 growth remain in focus.
View source ↗ - Newsfool.com·18d ago·Positive
Novo Nordisk: 3 Key Takeaways for Long-Term Investors Novo Nordisk added 1.3 million patients in the third quarter. Wegovy pill will reach over 20 markets by mid-2027.
View source ↗ - Newsfool.com·18d ago·Neutral
Novo Nordisk Stock Jumped After Earnings — But Its CEO Won't Give 2027 Guidance. Here's What Investors Should Know Novo Nordisk raised its 2026 outlook for the second time in three months, and the stock jumped about 5% on Wednesday. CEO Mike Doustdar wouldn't forecast 2027, but he listed three things helping next year's sales and three hurting them.
View source ↗ - News247wallst.com·18d ago·Neutral
Novo Nordisk Stock Jumps 6% as Wegovy Hits a Stunning 80% Milestone Novo Nordisk shares surged Wednesday on a single metric from the Wegovy earnings call that suggested the oral pill is reshaping the obesity market faster than Wall Street expected, even as prices fall and a rival closes in.
View source ↗ - Newszacks.com·18d ago·Neutral
NVO Q3 Earnings Beat Estimates on Wegovy Pill Growth, Outlook Raised Novo beats Q3 earnings and revenue estimates as Wegovy pill sales surge, driving a higher 2026 outlook despite diabetes weakness and pricing pressures.
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Novo Nordisk Q3: Just The Report I Was Waiting For Novo Nordisk A/S delivered a strong Q3 with a double beat and raised guidance, signaling a turnaround and renewed growth trajectory. Obesity care, especially the Wegovy pill, is driving revenue growth, offsetting declines in diabetes; international markets outperform the U.S. Margins have rebounded with an adjusted operating margin of 40.1%, and robust cash flow and interest coverage support financial strength.
View source ↗ - Newsbarrons.com·18d ago·Negative
2 Reasons for Hope From Novo Nordisk Earnings The Danish drugmaker has had a dismal year, but its third-quarter earnings on Wednesday finally gave the market a reason to feel hopeful.
View source ↗ - Newsmarketwatch.com·18d ago·Negative
Beleaguered Novo offers relief to investors, thanks to Wegovy pill Novo Nordisk stock jumped higher on Wednesday as the Danish drugmaker lifted its guidance on strong uptake of its weight-loss drug pill that was launched this year.
View source ↗ - Newswsj.com·18d ago·Negative
Novo Nordisk Lifts Guidance as Rollout of Wegovy Weight-Loss Pill Continues The Danish drugmaker raised its guidance for the year after noting an improved outlook for its key obesity and diabetes drugs, particularly in markets outside of the U.S.
View source ↗ - Newsreuters.com·18d ago·Neutral
Novo Nordisk's CFO Karsten Munk Knudsen to leave company Novo Nordisk's CFO Karsten Munk Knudsen to leave company
View source ↗ - Newscnbc.com·18d ago·Neutral
Novo raises full-year outlook as Wegovy sales impress Novo raises full-year outlook as Wegovy sales impress
View source ↗ - Newsreuters.com·18d ago·Positive
Novo Nordisk Q3 profit beats forecast; raises 2026 guidance Novo Nordisk Q3 profit beats forecast; raises 2026 guidance
View source ↗ - Newsfool.com·19d ago·Neutral
3 Dirt Cheap Dividend Stocks to Buy in November 2026 AT&T, Novo Nordisk, and Vici Properties have struggled this year but remain high-quality investments. Their valuations are incredibly low, giving investors the potential to benefit from high dividends and strong long-term returns.
View source ↗ - Newszacks.com·20d ago·Neutral
Novo Before Q3 Earnings: How Should Investors Play the Stock? NVO faces intensifying GLP-1 competition, earnings cuts and pricing pressure, challenging its growth outlook ahead of Q3 results.
View source ↗ - Newszacks.com·23d ago·Neutral
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
View source ↗ - Newsfool.com·24d ago·Positive
Novo Has Big Plans for 2030. Should You Buy the Stock Now? Novo plans to expand its lineup and pipeline by 2030, while serving far more patients. The company seems well positioned to accomplish many of its goals.
View source ↗ - Newszacks.com·26d ago·Neutral
Novo Nordisk (NVO) Stock Declines While Market Improves: Some Information for Investors In the latest trading session, Novo Nordisk (NVO) closed at $38.7, marking a -1.11% move from the previous day.
View source ↗ - Newsseekingalpha.com·26d ago·Positive
…Buy Both, But Lilly Is My Top Pick Eli Lilly and Company has decisively outpaced Novo Nordisk A/S in the GLP-1/obesity/T2D market, now commanding a $1.21T valuation. NVO's share price has retraced all post-Wegovy gains; revenue growth is stagnant, but management's reset and pipeline strategy prompt a Buy upgrade. LLY's pipeline, momentum, and manufacturing strength support continued dominance, with the potential to surpass $100B in annual revenues as early as next year.
View source ↗ - Newszacks.com·31d ago·Neutral
NVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains? Viking Therapeutics' late-stage obesity drug and promising weight-maintenance data could offer greater upside than Novo Nordisk, despite higher clinical and commercial risks.
View source ↗ - Newsfool.com·32d ago·Negative
Where Will Novo Stock Be in 10 Years? Novo remains a leader in the diabetes and weight loss drug markets. The company could make significant clinical and regulatory progress over the next few years.
View source ↗ - Newscnbc.com·33d ago·Negative
Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy. The Danish company said its next-generation obesity drug showed 25% weight loss on average at 68 weeks among adult women in a new analysis conducted after a late-stage trial.
View source ↗ - Newszacks.com·34d ago·Positive
Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why In the most recent trading session, Novo Nordisk (NVO) closed at $38.42, indicating a -1.06% shift from the previous trading day.
View source ↗ - Newszacks.com·34d ago·Positive
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now? Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
View source ↗ - Newszacks.com·40d ago·Neutral
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today In the latest trading session, Novo Nordisk (NVO) closed at $38.06, marking a -1.35% move from the previous day.
View source ↗ - Newsseekingalpha.com·45d ago·Positive
Novo Nordisk Vs. Eli Lilly: Judged Against Big Pharma, Only One Needs A Premium Novo Nordisk is rated Buy versus Hold for Eli Lilly, anchored by a compelling valuation discount to big pharma peers. NVO trades at ~11.2x 2027 earnings, a ~26% discount to peer median, despite consensus growth rates in line with peers and a robust yield. The investment case does not require a rerating; ~10% annual returns are achievable if current discounted valuations hold and yield continues.
View source ↗ - Newszacks.com·46d ago·Negative
Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to Know Novo Nordisk (NVO) reached $38.26 at the closing of the latest trading day, reflecting a +1.95% change compared to its last close.
View source ↗ - Newszacks.com·46d ago·Neutral
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care? Novo's semaglutide expansion into liver disease and other obesity-related conditions can unlock growth, but competition and clinical risks loom.
View source ↗ - Newszacks.com·47d ago·Neutral
Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now? Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
View source ↗ - Newszacks.com·48d ago·Neutral
Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work NVO's denecimig FDA review is delayed by manufacturing facility remediation, while no clinical efficacy or safety deficiencies were identified.
View source ↗ - Newsreuters.com·51d ago·Negative
US FDA extends review of Novo Nordisk's hemophilia drug over facility issues The US FDA has extended its review of Novo Nordisk's experimental hemophilia A drug due to ongoing remediation work at a manufacturing facility, the Danish drugmaker said on Friday.
View source ↗ - Newsglobenewswire.com·51d ago·Negative
Novo provides update on the denecimig Biologics License Application (BLA) in the US Bagsværd, Denmark, 02 October 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed Novo that the BLA review of denecimig for the treatment of haemophilia A, with or without inhibitors in adults and children, is still ongoing. The FDA has not communicated a new timeline for expected regulatory action on the BLA.
View source ↗ - Newsproactiveinvestors.com·51d ago·Negative
Eli Lilly obesity drug data adds pressure on Novo Nordisk Novo Nordisk (NYSE:NVO) faces further pressure in the obesity-drug market after Eli Lilly and Co (NYSE:LLY) reported promising mid-stage data for an experimental treatment that delivered greater weight loss than tirzepatide alone. EloraTZP, a combination of eloralintide and tirzepatide targeting amylin, glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 pathways, produced weight loss of up to 23.3% after 48 weeks in …
View source ↗ - Newszacks.com·53d ago·Neutral
NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk Novo's real-world study finds that patients who increase their Ozempic to 2 mg have a lower observed MACE risk than those who switch to Mounjaro.
View source ↗ - Newszacks.com·53d ago·Negative
Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines? NVO's latest Hengrui deal adds a phase I-ready, once-weekly oral GLP-1/GIP candidate, building on deals for oral drug-delivery tech and small-molecule approaches.
View source ↗ - Newsreuters.com·53d ago·Negative
Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study Patients who switched from weight-loss injections to Novo Nordisk's daily Wegovy pill continued to lose weight, according to data unveiled at a medical meeting on Wednesday, as the Danish drugmaker seeks to defend its lead over US rival Eli Lilly in the market for oral obesity treatments.
View source ↗ - Newscnbc.com·53d ago·Negative
People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study People who switched from obesity injections to Novo's new Wegovy pill continued to lose weight after three months, according to an analysis of real-world data the company presented. Patients who switched from either a Wegovy shot or Lilly's Zepbound injection to the Wegovy pill and stayed on treatment for three months lost roughly 4% of their weight on average.
View source ↗ - Newsfool.com·53d ago·Neutral
Novo Nordisk Gives Uninspiring Outlook Investors were hopeful for a better growth estimate.
View source ↗ - Newszacks.com·54d ago·Neutral
Novo Nordisk (NVO) Dips More Than Broader Market: What You Should Know Novo Nordisk (NVO) concluded the recent trading session at $38.31, signifying a -1.03% move from its prior day's close.
View source ↗ - Newsseekingalpha.com·54d ago·Positive
Novo Nordisk: After A 70+% Drop, It's A Great Investment Novo Nordisk remains a compelling long-term investment despite a 70% share price decline amid GLP-1 competition. NVO's diversified portfolio, robust R&D pipeline, and rare disease milestones support improved 2026 guidance and international sales momentum. Free cash flow yield is set to rise as capex normalizes, with guidance for 7.6 billion USD FCF and a 4.6% dividend yield.
View source ↗ - Newsmarketwatch.com·54d ago·Positive
Novo Nordisk strikes second licensing deal since frosty capital-markets day Novo Nordisk on Tuesday struck its second licensing deal since receiving a poor reception from investors after presenting its long-term strategy.
View source ↗ - Newsreuters.com·54d ago·Negative
China's Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug Jiangsu Hengrui Pharmaceuticals , China's largest drugmaker by market value, said on Tuesday it will license global rights to its weight-management drug HRS-1596 to Novo Nordisk A/S in a deal worth up to $2.6 billion.
View source ↗ - Newsfool.com·57d ago·Neutral
Lilly Cut an Obesity Drug -- but the Move Shows How High Its Bar Has Become Eli Lilly is the leader in the GLP-1 space, but not every new drug the company is working on will be a winner.
View source ↗ - Newsfool.com·58d ago·Negative
Could This Be Novo Nordisk's Next Billion-Dollar Weight-Loss Product? Novo Nordisk needs new products to better compete with Eli Lilly in the weight loss market. Zenagamtide is one of its promising candidates and could, eventually, generate over $1 billion in annual sales.
View source ↗ - Newszacks.com·58d ago·Neutral
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
View source ↗ - Newscnbc.com·58d ago·Negative
Pharma stock soars 150% on injectables deal with Wegovy maker Novo The Swedish drug-delivery company agreed to license its PharmaShell technology to Novo Nordisk for up to five development programs targeting obesity, type 2 diabetes and other cardiometabolic conditions. Novo Nordisk will use the technology to develop injectable drugs that could be administered monthly or quarterly, with Nanexa eligible for upfront and milestone payments as well as royalties on future sales.
View source ↗ - Newswsj.com·58d ago·Negative
Novo Nordisk to Pay Up to $1.3 Billion for Nanexa's Drug Delivery Technology Novo Nordisk agreed to license and develop the technology, which could cut the frequency patients need to inject its obesity and diabetes drugs.
View source ↗ - Newsreuters.com·58d ago·Negative
Nanexa shares soar on €1.17 billion Novo Nordisk deal for injection technology Shares in Swedish drug-delivery company Nanexa more than doubled their value in early Friday trading after it signed a global licensing deal with Novo Nordisk worth up to about €1.17 billion ($1.33 billion).
View source ↗ - Newsseekingalpha.com·59d ago·Neutral
Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine At its September 21 Capital Markets Day, Novo Nordisk A/S outlined plans to launch more than five multi-blockbusters by 2030 and deliver over DKK 150 billion in pipeline sales by 2035. CEO Maziar Doustdar said Novo will prioritize asset quality over deal size, with bolt-on acquisitions likely to be the focus while remaining open to larger deals. Meanwhile, in Q2, sales of the Wegovy pill were up 42.6% quarter-on-quarter to about DK
View source ↗ - Newscnbc.com·59d ago·Negative
Novo's new strategy hinges on something it can't manufacture: investor trust Novo set out ambitions to launch more than five potential multi-blockbuster drugs by 2030 on Monday, but shares fell 8%. Analysts said the update offered little new to restore confidence after the company's shares tumbled over the past two years.
View source ↗ - Newszacks.com·60d ago·Neutral
Novo Nordisk (NVO) Falls More Steeply Than Broader Market: What Investors Need to Know Novo Nordisk (NVO) closed the most recent trading day at $38.17, moving 3.12% from the previous trading session.
View source ↗ - Newsproactiveinvestors.com·60d ago·Negative
Novo Nordisk open to direct New York listing, CEO says Novo Nordisk (NYSE:NVO) (NYSE:NVO), the Danish drugmaker, would be open to considering a direct listing of its shares on the New York Stock Exchange, according to chief executive Mike Doustdar. Doustdar told the Financial Times that he could see advantages to such a move, although he clarified that the Danish pharmaceutical company is not currently exploring a change to its US listing structure.
View source ↗ - Newsreuters.com·60d ago·Negative
Novo Nordisk open to New York listing upgrade, CEO Doustdar tells FT Novo Nordisk is open to the idea of upgrading its New York listing as part of efforts to raise the Danish weight-loss drugmaker's profile in the country, its chief executive told Financial Times in an interview published on Wednesday.
View source ↗ - Newsreuters.com·61d ago·Negative
Novo CEO says pills could capture 50% of weight-loss market by 2030 Weight-loss pills could capture as much as half of the global obesity drug market by 2030, Novo Nordisk's chief executive told Reuters on Tuesday, as the Danish drugmaker positions itself for a shift away from weekly injections.
View source ↗ - Newsreuters.com·61d ago·Negative
Novo Nordisk and UNICEF renew push to prevent childhood obesity Novo Nordisk and UNICEF have expanded their partnership to help prevent childhood overweight and obesity, the Danish drugmaker said on Tuesday.
View source ↗ - Newscnbc.com·61d ago·Negative
Novo CEO signals M&A opportunities to strengthen drug pipeline Novo CEO Mike Doustdar told CNBC it's mulling M&A opportunities amid increasing competition. In this article NVO
View source ↗ - Newsyoutube.com·62d ago·Neutral
Monday's Final Takeaways: NVO Stumbles in GLP-1 Race, U.S.-China Summit Begins Eli Lilly (LLY) is gaining speed in capturing the GLP-1 craze as Novo (NVO) continues to struggle in catching a bullish bid. Meanwhile, the U.S.-China summit begins with President Trump and China President Xi Jinping poised to meet on Thursday.
View source ↗ - Newsglobenewswire.com·62d ago·Neutral
Novo Resources Releases Updated Corporate Presentation PERTH, Australia, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) is pleased to announce the release of its updated corporate presentation, now available on the Company's website.
View source ↗ - Newsmarketbeat.com·62d ago·Positive
Novo Nordisk Targets Five Multi-Blockbusters by 2030 as Oral Wegovy Gains Traction Novo Nordisk A/S NYSE: NVO outlined an updated strategy at its Capital Markets Day centered on diabetes and obesity, expansion into blood and endocrine disorders, liver disease and cardiovascular conditions, and a growing focus on consumer-facing prescription medicine channels.
View source ↗ - Newsproactiveinvestors.com·62d ago·Negative
Novo Nordisk shares plunge over 7% as new targets fail to reassure investors Novo Nordisk (NYSE:NVO), the Danish drugmaker, saw its US-listed shares fall over 7% to $39.82 on Monday after new long-term targets failed to ease investor concerns about competition in the weight-loss drug market. The company said it aims to launch more than five multi-blockbuster drugs by 2030 and generate more than 150 billion Danish kroner (US$23 billion) in risk-adjusted pipeline sales by 2035, including current p…
View source ↗ - Newszacks.com·62d ago·Positive
Novo's Sogroya Gains CHMP Nod for Idiopathic Short Stature in the EU NVO's Sogroya wins a positive CHMP opinion for idiopathic short stature in the EU, potentially broadening its pediatric growth disorder reach.
View source ↗ - Newsschaeffersresearch.com·62d ago·Negative
Novo Shares Slip as Growth Plan Disappoints Investors Novo Nordisk (NYSE:NVO) shares are down 6.2% to trade at $40.55, after investors came away unimpressed about the drugmaker's pipeline amid increasingly crowded competition in the weight loss market.
View source ↗ - Newsbenzinga.com·62d ago·Neutral
Beyond Ozempic: Novo Nordisk Plots Next Decade Growth with Bigger Pipeline, Slimmer Workforce Novo Nordisk A/S (NYSE:NVO) on Monday outlined a broad strategic roadmap targeting sustained global expansion during its Capital Markets Day 2026 presentation.
View source ↗ - Newsbenzinga.com·62d ago·Neutral
Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining around 1% on Monday.
View source ↗ - Newsreuters.com·62d ago·Negative
Novo says its next-gen obesity drug tops Lilly rival in late-stage study Novo Nordisk said on Monday its next-generation experimental drug had achieved an estimated average weight loss of 12.4% in a late-stage trial and that it was superior to Eli Lilly's drug.
View source ↗ - Newsreuters.com·62d ago·Negative
Novo Nordisk aims to launch more than five blockbuster drugs by 2030, CEO says Novo Nordisk aims to launch more than five blockbuster drugs by 2030 and to deliver more than 150 billion Danish crowns ($23 billion) in pipeline sales in 2035, its CEO Mike Doustdar said at its Capital Markets Day in London.
View source ↗ - Newswsj.com·62d ago·Negative
Wegovy Maker Novo Nordisk Targets Several New Blockbuster Drugs in Coming Years Shares in Novo Nordisk fell more than 4% as its CEO laid out plans to launch new blockbuster drugs in the next few years while expanding into further treatment areas.
View source ↗ - Newswsj.com·62d ago·Negative
Wegovy Maker Novo Nordisk Targets Several New Blockbuster Drugs in Coming Years — Update Shares in Novo Nordisk fell more than 4% as its CEO laid out plans to launch new blockbuster drugs in the next few years while expanding into further treatment areas.
View source ↗ - Newsmarketwatch.com·62d ago·Negative
Novo Nordisk stock tumbles as Ozempic maker sets out 2030 goals Novo Nordisk stock tumbled on Monday as the weight-loss drug manufacturer failed to excite investors hoping for a turnaround.
View source ↗ - Newscnbc.com·62d ago·Negative
Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs
View source ↗ - Newsreuters.com·62d ago·Negative
Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs Wegovy-maker Novo Nordisk's CEO Mike Doustdar will face pressure on Monday to set out his strategy for competing with US rival Eli Lilly and how he plans to boost the company's growth beyond the blockbuster weight-loss drug.
View source ↗ - Newszacks.com·65d ago·Neutral
Novo's Denecimig Gets CHMP Nod for Hemophilia A in the European Union NVO's denecimig wins a positive European opinion for hemophilia A, with flexible dosing and a potential 2026 launch.
View source ↗ - Newszacks.com·66d ago·Negative
Novo Expands AI Push With Anthropic Deal to Accelerate Drug Discovery NVO is expanding its AI strategy with Anthropic to tackle drug discovery challenges, boost R&D productivity and develop new medicines faster.
View source ↗ - Newszacks.com·66d ago·Positive
Novo Falls 5% in a Week: How Should Investors Approach the Stock Now? NVO's 5% drop in a week reflects intensifying GLP-1 competition and semaglutide risks, but its broad pipeline offers potential long-term growth.
View source ↗ - Newsreuters.com·66d ago·Negative
Novo, Orbis sign up to $1.4 billion deal to develop oral drugs Orbis Medicines said on Thursday it had signed a drug discovery and licensing deal with Novo Nordisk worth up to $1.4 billion to develop oral therapies for cardiometabolic diseases that are traditionally treated with injectable drugs.
View source ↗ - Newszacks.com·67d ago·Neutral
Novo Nordisk (NVO) Registers a Bigger Fall Than the Market: Important Facts to Note Novo Nordisk (NVO) closed the most recent trading day at $41.67, moving 2.02% from the previous trading session.
View source ↗ - Newsbarrons.com·67d ago·Negative
Will AI Save the Pharma Industry Billions? Novo's Anthropic Deal Is Betting on It. Novo Nordisk and Anthropic strike a partnership to leverage Claude and other AI models in the drug development process.
View source ↗ - Newszacks.com·69d ago·Negative
Will Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes? Novo faces a tougher growth outlook as Morgan Stanley downgrades the stock to Underweight, citing muted growth, patent risks and rising pressure from Lilly.
View source ↗ - Newszacks.com·69d ago·Neutral
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
View source ↗ - Newsreuters.com·69d ago·Negative
Novo Nordisk rebrands as 'Novo', announces cultural reset Novo Nordisk is changing its day-to-day name to 'Novo', and taking a new approach to company culture as it looks to claw back ground in the fierce obesity drug race, the Danish drugmaker said on Monday.
View source ↗ - Newswsj.com·69d ago·Negative
Novo Nordisk to Rebrand as Novo The drugmaker said its new name aims to make it more recognizable to compete in the market for obesity medications.
View source ↗ - Newscnbc.com·69d ago·Negative
Novo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market share Novo Nordisk said it is rebranding its name to "Novo" and updating its corporate culture, as the company works to win back market share in the obesity drug space. The Danish drugmaker called the changes the beginning of a new chapter, as it faces stiff competition from Eli Lilly and investor pressure to deliver new blockbuster products.
View source ↗ - Newsfool.com·70d ago·Neutral
Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst Novo Nordisk launched its Wegovy pill in early 2026, with Eli Lilly quickly following with a pill called Foundayo. Novo Nordisk's pill has been very well received, while Eli Lilly's pill has been slower to gain traction.
View source ↗ - Newszacks.com·73d ago·Neutral
Novo Nordisk (NVO) Suffers a Larger Drop Than the General Market: Key Insights Novo Nordisk (NVO) closed the most recent trading day at $44.01, moving 1.23% from the previous trading session.
View source ↗ - Newsseekingalpha.com·73d ago·Positive
Novo Nordisk: Valuation Reflects High Risk, But Solid Margin Of Safety Novo Nordisk remains a Strong Buy after a robust Q2, with another guidance boost and strong free cash flow growth. NVO's valuation reflects high risk, yet intrinsic value estimates suggest a significant discount to current market price. GLP-1 market leadership persists, but competitive and regulatory pressures, plus post-LOE strategy execution, are critical forward risks.
View source ↗ - Newsreuters.com·73d ago·Negative
Novo Nordisk says Wegovy approved in China for liver disease MASH Denmark's Novo Nordisk said on Thursday its blockbuster weight-loss drug Wegovy had been approved in China as the first GLP-1 RA class of drugs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
View source ↗ - Newsyoutube.com·76d ago·Negative
Ozempic maker: We sold health when people wanted weight loss Novo Nordisk invented the GLP-1 category, told the world that weight loss was the least important thing its drugs did, and then watched a competitor take market share by promising a bigger number. Mike Doustdar became president and CEO of Novo Nordisk in August 2025, after 34 years at the company that began with a summer job making photocopies in its Vienna office.
View source ↗ - Newsreuters.com·76d ago·Negative
Novo scraps two more heart drug trials, further dimming growth beyond obesity Novo Nordisk said on Monday it had halted two additional trials of its experimental cardiovascular drug ziltivekimab, further denting the Danish drugmaker's efforts to diversify beyond its blockbuster obesity and diabetes franchise.
View source ↗ - Newswsj.com·76d ago·Negative
Novo Nordisk Says Wegovy Shot Helped Children Lose Weight in Trial The Danish drugmaker said the clinical trial met its primary goal after 68 weeks of treatment.
View source ↗
Earnings
Wed, Feb 3(in 2 months)
Consensus estimate $0.68 per share
Typical surprise +17.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$0.89 vs $0.72beat
- Wed, Aug 5$0.96 vs $0.82beat
- Wed, May 6$1.04 vs $0.87beat
- Tue, Feb 3$1.00 vs $0.90beat
- Wed, Nov 5$1.02 vs $0.77beat
- Wed, Aug 6$0.97 vs $0.93beat
Estimates and results for NVO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Kevin Hernhouse · OK01 · disclosed Sep 28, 2026 (28d later)Sell$1,001 - $15,000
- Kevin Hernhouse · OK01 · disclosed Sep 28, 2026 (18d later)Sell$1,001 - $15,000
- Scott Franklinhouse · FL18 · disclosed Sep 18, 2026 (23d later)Buy$1,001 - $15,000
- Scott Franklinhouse · FL18 · disclosed Sep 18, 2026 (23d later)Buy$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (113d later)Buy$15,001 - $50,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (24d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Oct 22, 2025 (41d later)Buy$1,001 - $15,000
- Marjorie Taylor Greenehouse · GA14 · disclosed Oct 21, 2025 (6d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Sep 15, 2025 (42d later)Sell$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Sep 12, 2025 (318d later)Buy$1,001 - $15,000
- Marjorie Taylor Greenehouse · GA14 · disclosed Sep 1, 2025 (4d later)Buy$1,001 - $15,000
- Marjorie Taylor Greenehouse · GA14 · disclosed Aug 21, 2025 (2d later)Buy$15,001 - $50,000
- Scott Franklinhouse · FL18 · disclosed Aug 15, 2025 (11d later)Buy$15,001 - $50,000
- Scott Franklinhouse · FL18 · disclosed Aug 15, 2025 (11d later)Buy$1,001 - $15,000
- Scott Franklinhouse · FL18 · disclosed Aug 15, 2025 (11d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (65d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (34d later)Sell$1,001 - $15,000
- Laurel Leehouse · FL15 · disclosed Jun 23, 2025 (46d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
